Progression-free survival longer with T-DXd versus T-DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Sept. 24, 2021 (HealthDay News) — For patients with HER2-positive metastatic breast cancer (mBC) previously treated with trastuzumab and taxane, trastuzumab deruxtecan (T-DXd) yields a significant improvement in progression-free survival compared with trastuzumab emtansine (T-DM1), according to a study presented at the annual meeting of the European Society for Medical Oncology, held virtually from Sept. 16 to 21.<\/p>\n
Javier Cort \u00a9s, M.D., Ph.D., from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, and colleagues compared the efficacy and safety of T-DXd versus T-DM1 in patients with HER2-positive mBC previously treated with trastuzumab and taxane. A total of 524 patients were randomly assigned in a 1:1 ratio as of May 21, 2021.<\/p>\n
The researchers found that the hazard ratio was 0.2840 for progression-free survival (median not reached for T-DXd versus 6.8 months for T-DM1). The estimated 12-month overall survival event rates were 94.1 and 85.9 percent for T-DXd and T-DM1, respectively (hazard ratio, 0.5546; did not cross prespecified boundary for significance). The median treatment duration was 14.3 and 6.9 months with T-DXd and T-DM1, respectively. The rates of treatment-emergent adverse events were similar.<\/p>\n
“T-DM1 became the standard of care second-line therapy in 2013 and is the first U.S. Food and Drug Administration-approved antibody drug conjugate. It has a solid safety and efficacy profile,” senior author Sara Hurvitz, M.D., director of the Breast Cancer Clinical Research Program at the UCLA Jonsson Comprehensive Cancer Center, said in a statement. “In the past eight years we have not seen any other therapy try to beat it in a head-to-head trial. Seeing a new therapy demonstrate such a substantial improvement in progression-free survival compared to T-DM1 is really exciting for our patients.”<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Daiichi Sankyo and AstraZeneca, which manufacture T-DXd and funded the study.<\/p>\n
Press Release<\/a><\/p>\n